Navigation Links
Debiopharm and EPFL Establish an Oncology Chair
Date:2/27/2008

LAUSANNE, Switzerland, February 27 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, today announced the establishment of a Debiopharm oncology chair at the Ecole Polytechnique Federale de Lausanne (EPFL), focusing on Signal Transduction in Oncogenesis. Funded through a CHF 2.5 million endowment, the objective of the chair is to leverage the wide scope of ideas and inventions discovered by EPFL scientists and the global drug development expertise of Debiopharm. The synergy expected through this partnership will maximise the chances of bringing innovative drugs to patients.

The Debiopharm oncology chair will support the research work of Assistant Professor Dr Joerg Huelsken, of the EPFL Faculty of Life Sciences, which focuses on the role of the WNT signalling pathway in tumorigenesis and stem cell maintenance. Under the terms of the agreement, Debiopharm will also finance other potential collaborative research projects of mutual interest to both parties and will have the option to endow a second chair in Drug Design.

"The creation of this oncology chair will reinforce our involvement in local research," said Kamel Besseghir, CEO of Debiopharm S.A. "We are in close vicinity to the EPFL and have been collaborating on various projects over the past years. Our recently established office at the EPFL will contribute to build a critical mass in biomedical research in the Lake Geneva region, help us identify new projects and blend our ideas."

"The timing of our oncology chair at the EPFL could not have been better. The move of ISREC (Swiss Institute for Experimental Cancer Research) to the EPFL this year will increase their concentration of oncology expertise," added Rolland-Yves Mauvernay, President and Founder of Debiopharm Group."

"This partnership with Debiopharm is an example of how academic research and pharmaceutical industries can collaborate to develop promising therapies for the benefit of patients," said Didier Trono, Dean of the Life Science Faculty at the EPFL.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2006.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com

Debiopharm S.A. Contacts:

Kim Bill

VP Corporate Development

Tel: +41(0)21-321-01-11

Fax: +41(0)21-321-01-69

kbill@debiopharm.com

Additional Media Contacts:

In London

Maitland

Brian Hudspith

Tel: +44(0)20-7379-5151

bhudspith@maitland.co.uk

In New York

Russo Partners, LLC

Wendy Lau

Tel: +1-212-845-4272

Fax: +1-212-845-4260

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
2. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
3. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care
6. European Centre for Modern Drug Discovery Established in Hamburg
7. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. KGI and Smith College Establish Leadership Forum for Women in Bioscience
10. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
11. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building ... corporate rebranding initiative announced today. The bold new look is part of a ... company moves into a significant growth period. , It will also expand its service ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks ... Strategy, will speak at the TMA 2017 Annual Meeting , October ... trends in the residential home security market and how smart safety and ... Parks ... "The residential ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
Breaking Biology News(10 mins):